Orzaks Ilac Ve Kimya Sanayi Ticaret A.s. · BIST:ORZAX
Orzaks Ilac Ve Kimya Sanayi Ticaret A.s — IPO Roadshow (June 2026)
57 slides from Orzaks Ilac Ve Kimya Sanayi Ticaret A.s's IPO roadshow presentation, June 2026
Slide 1: The Leader of the Food Supplements Sector
THE LEADER OF THE FOOD SUPPLEMENTS SECTOR* ORZAX STRONG ROOTS IN HEALTH INVESTING IN THE FUTURE TOGETHER eee G €& orzax.com.tr ) “According to |QVIA 2025 market data, based on total market data for non-pharmaceutical praducts in which Orzax products are included,
Slide 2: Content
Content Executive Overview About Us Sector Key Investment Elements Financials Use of Fund Information on Public Offering
Slide 3: Executive Overview
EXECUTIVE & OVERVIEW
Slide 4: Executive Overview
4 > Executive Overview Executive Overview Main Areas of Activity Main Partner: Yunus Emre Alimoğlu (%51.8) Alyors Sağlık ve Gıda Teknolojileri Sanayi Ticaret A.Ş. (%48.2) Regulato ry A Field of Activity: Production, sales, and marketing of dietary supplements D ut h R& or Foundation: 2004 iza tio Lo
Slide 5: Highlights
5 > Executive Overview Highlights
Slide 6: About Us
ABOUT US
Slide 7: About Us
7 > About Us Our company offers a broad portfolio of dietary supplements and cosmetics. Our products include Omega 3, vitamin mineral supplements, herbal extracts, probiotics, collagen and chewa- ble gel form supplements. These products are distributed to approximately 30,000 phar- macies through ph
Slide 8: Shareholding Structure
8 > About Us Shareholding Structure Alyors Health Yunus Emre Alimoğlu %48.2 %51.8 Nuvita Pharmaceuticals Orzax GmbH - Germany Orzax Inc. - USA Orzax Ltd. - England Orzax Sp Zoo - Poland Too Orzax - Kazakhstan Too Orzax Central Asia ORZAX L.L.C-FZ and Chemicals. Orzaks %75 Orzaks %100 Orzaks %100 Orz
Slide 9: Board of Directors Resumes
9 > About Us Board of Directors Resumes CHAIRMAN OF THE BOARD SELMAN ALİMOĞLU Selman Alimoğlu was born in Elazığ in 1975 and graduated from Istanbul University Faculty of Pharmacy in 1999. He began his professional career in Elazığ and subsequently moved to Istanbul. He served as General Manager of
Slide 10: Milestones
10 > About Us Milestones • 873 employees (as of 30.06.2024) • Export to 48 countries • Cooperation with 92 customers in various countries Turkey OTC • Foundation of • 5 locations Start-up of the England Company • Successfully passed FDA inspection. production market leadership • SHINIQ Enters the •
Slide 11: Personnel Chart by Years
11 > About Us Personnel Chart by Years 1016 968 783 686 621 542 545 471 440 415 367 426 344 368 324 342 283 297 649 157 31.12.2021 31.12.2022 31.12.2023 31.12.2024 31.12.2025 31.03.2026 White Collar Blue Collar Total
Slide 12: Nuvita Production Line
12 > About Us Nuvita Production Line Tablet Sachet 501 million/year 69,5 million/year Capsule Effervescent 150 million/year 40 million/year Softgel Liquid 362 million/year 33,5 million/year
Slide 13: Nuvita Production Center and R&D Center
13 > About Us Nuvita Production Center R&D Center Nuvita is one of Turkey’s leading manu- Nuvita conducts its R&D activities at the facturers of pharmaceuticals, food sup- Nuvita Biosearch Center (NBC), approved plements and cosmetics with a high-qual- by the Ministry of Industry and Technolo- ity p
Slide 14: R&D and Quality Assurance
14 > About Us R&D and Quality Assurance Our products are developed to meet international standards with an innovative approach in formulation determination, raw material and packaging material selection during the R&D phase and are monitored and analyzed at every stage of production. All formulation
Slide 15: Technology and R&D: First and Only in Turkey
15 > About Us Technology and R&D First and Only in Turkey 1. Probiotic raw material production from isolated bacteria from breast milk and newborn feces samples in Turkey (30 types of probiotics) 2. Vegan omega 3, vitamin D, beta carotene, astaxanthin synthesis from microalgae 3. The only laboratory
Slide 16: Certificates
16 > About Us Certificates FDA Certificate GMP Certificate Halal Certificate ISO Certificates Zero Waste Certificate 2025 CERTIFICATE OF REGISTRATION This certifies that: Nuvita Ilac Ve Kimya San. Tic. A.S. Akcaburgaz Mah 153.sok No:27/A Esenyurt Istanbul, Istanbul TR-34522 Turkey is registered with
Slide 17: Our Business Model
17 > About Us Our Business Model Research and Market Research Development (R&D) Regulatory Authorization Objective: Identify target markets and Objective: Development of planned Objective: To ensure compliance of consumer demands. products and continued improvement/ products with legal regulations a
Slide 18: Our Business Model
18 > About Us Our Business Model Distribution Channels Production Product Shipment and Collection Marketing and Sales Objective: To produce products in Objective: Dispatch of finished products to Objective: To increase the market share of accordance with the legislation and pharmaceutical warehouses
Slide 19: Product Categories
19 > About Us Product Categories Omega 3 Series Vitamins D Vitamins Magnesiums Probiotics Special Supplements Musculoskeletal Series Immunity Series Gummies Series Women Health Series Antioxidants Herbal Extracts Digestive Enzyms Mood Series Dermacosmetics
Slide 20: Product Portfolio
20 > About Us Product Portfolio
Slide 21: Sector
SECTOR
Slide 22: Annual Average Macroeconomic Expectations
22 > Sector Annual Average Macroeconomic Expectations 100 64 75 56 47 50 28 18 25 13 2026 2027 2028 Average USD/TRY Year-End Inflation (%)
Slide 23: World Food Supplements Market
23 > Sector World Food According to Grandview Research data, the global dietary supple- ments market size reached $192.65 billion in 2024, and this market is expected to grow at a compound annual growth rate of 8.9% from Supplements Market 2025 to 2033. According to IADSA data, the global vitamins a
Slide 24: World Dietary Supplements Market
24 > Sector The breakdown of the global vitamins and dietary supplements market by region and market size is shown in the table below, based on data for 2020-2024. World Dietary Supplements Market Region Market Size Asia-Pacific 62.1 billion $ North America 40,4 billion $ Western Europe 15.5 billion
Slide 25: World Dietary Supplements Market
25 > Sector World Dietary Supplements Market Historical CAGR 2020-24 Forecast CAGR 2025-29 180,000 160,000 %5,4 %2,3 140,000 Billion USD 120,000 100,000 80,000 60,000 40,000 20,000 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 Source: Passport (Consumer Health 2024) http://iadsa.org/global-marke
Slide 26: Food Supplements Global Positioning Category
26 > Sector Food Supplements Global Positioning Category 20 %16 18 %14 16 %12 Positioning Ratios 14 12 %10 10 %8 8 %6 6 %4 4 2 %2 0 0 h m m h s ty lth lth gy y h h s h h h rie t or alt alt alt alt alt alt alt uc ste ste au ea ea er em go He He He He He He He od Be En Sy Sy tH tH te M Pr l ne 's e ng
Slide 27: Key Investment Elements
. KEY INVESTMENT _ ELEMENTS ¢, Sil tig
Slide 28: Key Investment Elements
28 > Key Investment Elements Key Investment Elements The probiotic strains obtained as a result of the studies carried out at the NBC R&D center are thought to meet an important requirement of the market both as raw materials and finished products. This investment is the first and only investment in
Slide 29: Key Investment Elements
29 > Key Investment Elements Key Investment Elements High Profitability and The company’s consistently high EBITDA margin over the years demonstrates that it has managed its operational processes extremely efficiently, maintained its profitability in a sustainable manner Added Value despite fluctuat
Slide 30: Incentives
30 > Key Investment Elements Incentives R&D Corporate Export SSI Incentives Tax Incentives Personnel Incentives (Turquality) Subsidies
Slide 31: Nuvita is the Fastest Growing Company
31 > Key Investment Elements Nuvita is the Fastest Growing Company In line with the principles of sustainable development, Nu- vita produces products that improve the quality of life by fulfilling its social and ethical responsibilities; Nuvita offers solutions that create value to create a healthie
Slide 32: R&D expenditure ranking
32 > Key Investment Elements Nuvita İlaç ve Kim. Tic. A.Ş. 49 40 2023: $884.442 2024: $1.677.231 2025: $2.125.000 In 2024, we ranked 248th among the companies with the highest R&D expenditure and 65th among the companies conducting the highest number of R&D projects.
Slide 33: Financials
FINANCIALS
Slide 34: Consolidated Proforma Income Statement
34 > Financials ORZAKS İLAÇ VE KİMYA SANAYİ TİCARET ANONİM ŞİRKETİ AND ITS SUBSIDIARIES CONSOLIDATED PROFORMA INCOME STATEMENT (USD) FOR THE PERIODS ENDED DECEMBER 31, 2022, DECEMBER 31, 2023, DECEMBER 31, 2024, JANUARY 1 - JUNE 30, 2024, AND JANUARY 1 - JUNE 30, 2025 Audited Audited Audited Audited
Slide 35: Consolidated Proforma Balance Sheet
35 > Financials “ORZAKS İLAÇ VE KİMYA SANAYİ TİCARET ANONİM ŞİRKETİ AND ITS SUBSIDIARIES CONSOLIDATED PROFORMA BALANCE SHEET (USD) FOR THE PERIODS ENDED MARCH 31, 2026 Audited Prior Period Assets 31.03.2026 Current Assets Cash and Cash Equivalents 21.655.165 Trade Receivables 65.974.321 Inventories
Slide 36: Strong Financial Ratios
36 > Financials Strong Financial Ratios Liquid Balance Sheet Low Net Debt / EBITDA Ratio Profit Margins Indicating High Value Creation 2023 2024 2025 Reference Liquidity Ratios Current Ratio 1,57 1,85 1,80 1,0-1,5 Quick Ratio 1,20 1,40 1,28 0,8-1,0 Leverage Ratios Total Liabilities / Total Assets 60
Slide 37: Debts
37 > Financials Debts Financial Debts (Million USD) Net Debt (Million USD) 40 29,5 98,9 22,3 74,2 20 11,8 36,3 35,8 0 2023 2024 2025 31.03.2026 2023 2024 2025 31.03.2026 +10 -4,2 Net Debt / Equity (%) Net Debt / EBITDA 48 50 1 39 0,5 40 0,5 0,4 14 0,2 25 0,2 0 2023 2024 2025 31.03.2026 0 2023 2024 2
Slide 38: Net Sales and EBITDA
38 > Financials O RZAX Net Sales (Million USD) %30 CAGR 2023 - 2027T EBITDA (Million USD) %23 CAGR 2023 - 2027T
Slide 39: Orzaks Market Leader in OTC (Box)
39 > Financials Orzaks Market Leader in OTC (Box) ORZAKS The other 682 Company March 2026 March 2026 companies %24,85 YTD Unit YTD Market Share % 1. ORZAKS 6.626.073 24,85% %41,57 2. Company 2.279.329 8,55% 2.Company %8,55 3. Company 1.340.290 5,03% 4. Company 1.084.755 4,07% 5. Company 1.049.699 3,
Slide 40: Orzaks Category Based Market Share (Box)
40 > Financials Orzaks Category Based Market Share (Box) Other OTC YTD Orzaks YTD Orzaks YTD Joint Health %9,37 Category March 2026 March 2026 March 2026 Box %22,48 Box Market Unit Market Market Share % Vitamin D Vitamin D 2.360.047 1.680.195 71,19% Collagen %71,19 Omega 3 2.048.134 848.671 41,44% %
Slide 41: Category-Based Revenue (Including Export and OEM)
41 > Financials Category-Based (Including Export and OEM) Revenue (USD) Categories 31.12.2023 31.12.2024 31.12.2025 31.03.2025 31.03.2026 Immunity Vitamins and Minerals 53.253.480 58.156.914 88.799.525 22.962.194 33.724.799 Omega 3 18.469.738 17.695.536 24.026.845 6.348.623 8.837.066 %6,3 Herbal Ext
Slide 42: Geographical Regions
42 > Financials Geographical Regions Revenue (USD) Aegean Region %12 REGIONS 31.12.2023 31.12.2024 31.12.2025 31.03.2025 31.03.2026 Mediterranean Region 20.504.585 14.750.538 18.370.677 4.793.900 6.757.616 Eastern Anatolia Region 5.002.832 3.598.925 5.077.038 1.324.873 1.867.578 Aegean Region 21.765
Slide 43: Export Map
43 > Financials Export Map USA Abkhazia Albania Exports to Azerbaijan Bahrain Bangladesh 50+ Belarus Bosnia and Herzegovina Kazakhstan Countries Bulgaria Kosovo Cameroon Kuwait Croatia Kyrgyzstan France Latvia Mongolia Russia Tajikistan Gabon Liberia Morocco Saudi Arabia Trinidad and Tobago Georgia
Slide 44: Export Revenue and Export Sales
44 > Financials Export Revenue (USD) Russian Other 35 EXPORT 2023 2024 2025 31.03.2025 31.03.2026 Countries Federation 1 Russian Federation 45.593 4.287.550 5.377.870 1.560.958 1.306.142 %38,3 %39,1 2 Iraq 0 0 441.092 0 306.615 3 USA 413.047 308.833 184.894 60.192 177.296 4 Saudi Arabia 156.177 352.
Slide 45: Volume of Sales (Millions of Units)
45 Volume of Sales (Millions of Units) CAGR 2021-2025 CAGR 2025-2028 60 %27,1 %19,5 50 43,6 38 34, 8 40 32,3 31,2 30 25,5 27,2 19,5 20 16,5 22, 3 13,2 9,8 17,7 15,4 10 12,4 8,8 9,4 6,8 5,1 1,8 3,2 0,8 1,1 0 0,4 2021 2022 2023 2024 2025 2026 2027 2028 Domestic Export
Slide 46: 3x Sales Growth Targeted by 2029
46 > Financials 3x Sales Growth Targeted by 2029 Income Statement 2022 2023 2024 2025 2025 1Ç 2026 1Ç 2026T 2027T 2028T 2029T Domestic Sales 78.365 121.194 120.460 152.971 39.919 56.270 210.763 292.395 370.832 436.601 International Sales 2.987 3.170 8.016 11.855 2.673 2.898 18.138 28.918 41.965 58.7
Slide 47: Historical and Estimated CAGR
47 > Financials Historical CAGR 2022-25 Estimated CAGR 2026-29 25.000.000 %27 %29 20.000.000 %26 %27 15.000.000 10.000.000 5.000.000 2022 2023 2024 2025 2025 1Ç 2026 1Ç 2026 2027 2028 2029 Net Sales EBITDA
Slide 48: Use of Fund
USE OF FUND
Slide 49: Use of Fund Allocation
49 > Use of Fund Fon Kullanım Yerleri 50% 30% 20% Will be used to Decreasing debt Use for finance ongoing will be used for strengtening and new principal and working capital investments. interest payments. *It has been decided to be able to switch between the above-mentioned fund utilization items b
Slide 50: Financing Ongoing and New Investments
50 > Use of Fund Financing Ongoing and New Investments • The company’s subsidiary Nuvita İlaç ve Kimya Sanayi Ticaret A.Ş. (Nuvita) produces raw materials such as Probiotics, Yogurt Bacteria, Omega 3, Beta Glucan, Beta Carotene, Astaxanthin, Vitamin E Alpha Tocopherol, Vitamin B12 Cyanocobalamin, Vi
Slide 51: Financing New Investments
51 > Use of Fund Financing New Investments • The company has decided to establish have a closed area of 19,000 m² on 90 a production facility in the Free Zone acres of land provided by the Kazakh of Turkistan, Kazakhstan, to manufac- government, is planned to be ready ture food supplement products f
Slide 52: Information on Public Offering
INFORMATION ON PUBLIC OFFERING
Slide 53: Information on Public Offering
53 > Information on Public Offering Issuer Orzaks İlaç ve Kimya Sanayi Ticaret A.Ş. Issued Capital $6.902.584 Capital Increase : $708.246 Partner Sale : $472.164 Public Offering Size Total : $1.180.409 Public Float Rate : %15,51 Partner Making the Public Offering Yunus Emre Alimoğlu Consortium Leade
Slide 54: Legal Notice
54 Legal Notice The information contained in this presentation has been prepared by Orzaks İlaç ve Kimya Sanayi Ticaret A.Ş. in connection with the public offering of the Company’s shares (the “Public Offering”) and the Company’s intention to be listed on Borsa Istanbul A.Ş. (“BIST”). This presentat
Slide 55: Legal Notice
55 Legal Notice The industry, market and competitive landscape data contained in this presentation has been sourced from official or third party sources to the extent possible. Third-party industry publications, studies and research generally state that the data contained in such sources is obtained
Slide 56: Legal Notice
56 Legal Notice These forward-looking statements should be considered only as of the date hereof. The Company cautions the addressees of this presentation that forward-looking statements do not constitute a guarantee of the Company’s future performance and that the Company’s actual financial positio
Slide 57: ORZAX
ORZAX C@& orzax.com.tr )
Orzaks İlaç ve Kimya Sanayi Ticaret A.Ş. — IPO Roadshow (June 2026) on 6ix